Dosing literacy
Tirzepatide Maintenance Doses
A maintenance dose is the dose someone continues on after escalation, chosen by a prescriber to balance effect against tolerability. Labelled maintenance options span the higher strengths, and there is no requirement to reach 15 mg. Whether a reduced dose preserves an achieved result is the question SURMOUNT-MAINTAIN was designed to test.
Key takeaways
- A maintenance dose is whichever tolerated dose a prescriber continues, not necessarily the maximum.
- Labelled maintenance options span the higher dose strengths.
- Reaching 15 mg is not required and is not appropriate for everyone.
- Whether a reduced dose preserves results is under study in SURMOUNT-MAINTAIN.
- Maintenance dose selection is individual and requires ongoing prescriber contact.
| Definition | The dose continued after escalation |
|---|---|
| Labelled options | Higher dose strengths, per prescribing information |
| Requirement to reach maximum | None |
| Reduced-dose maintenance evidence | SURMOUNT-MAINTAIN (Lancet 2026): 5 mg maintained -16.6% vs -9.9% placebo |
| Selection | Prescriber decision with ongoing monitoring |
How is a maintenance dose chosen?
By balancing the response achieved against the side effects experienced, with a prescriber assessing both. SURMOUNT-1 showed larger average reductions at higher doses, so there is a rationale for escalating — but someone achieving their clinical goals at a lower dose with fewer side effects has no automatic reason to go higher.
Can a maintenance dose be reduced later?
That is exactly what SURMOUNT-MAINTAIN was designed to investigate, and it reported its results in the Lancet in 2026: reducing to 5 mg maintained -16.6% bodyweight reduction against -21.9% on the maximum tolerated dose and -9.9% on placebo. What is also established is that stopping entirely produces substantial regain (SURMOUNT-4). Reducing under supervision is a different question from stopping.
Any reduction is a clinical decision made with monitoring, not a cost-saving measure to arrange independently.
Is a lower maintenance dose the same as microdosing?
No. Reduced-dose maintenance lowers a dose that already produced a result, under prescriber supervision. Commercially marketed microdosing starts below the studied range in the hope of proportional benefit at lower cost, and has no randomised evidence supporting it.
What the evidence shows
- A labelled range of maintenance dose options.
- Established evidence that full withdrawal produces regain.
What the evidence does not show
- That a reduced maintenance dose preserves results — unverified here.
- Which maintenance dose is right for you.
Related: Maintenance treatment · Maximum dose
How much does each dose step actually add?
| Dose | Mean reduction |
|---|---|
| 2.5 mg | 0% |
| 5 mg | 15.0% |
| 10 mg | 19.5% |
| 15 mg | 20.9% |
| Group | Tirzepatide | Semaglutide |
|---|---|---|
| Discontinued for GI effects | 2.7% | 5.6% |
How is a maintenance dose actually settled on?
It emerges rather than being chosen in advance. A prescriber escalates while response continues and tolerability holds, and stops where those two curves cross. For some people that is 5 mg; for others 15 mg. The label provides the ladder, not the destination.
This is why asking what dose someone else settled at tells you very little. The same maintenance dose can represent a comfortable plateau for one person and the ceiling of tolerance for another.
What changes financially once maintenance is reached?
The cost stops being a temporary expense and becomes a standing one. During escalation it is possible to think of the spend as an experiment with an endpoint. At maintenance, with the withdrawal evidence showing regain after stopping, the realistic frame is an ongoing monthly cost with no defined end date.
That shift is worth making deliberately rather than drifting into it. Modelling two or three years at the maintenance-dose price — including any dose-related surcharge — is the calculation that actually matters, and it is rarely the one presented at enrolment.
What does this page cover, and what does it deliberately leave out?
This page addresses Approved options and maximum tolerated dose and reduced-dose research, organised around the primary question of tirzepatide maintenance dose. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Approved options | Covered on this page | Primary evidence |
| Maximum tolerated dose and reduced-dose research | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with your prescriber or dispensing pharmacist |
What are the limits of what this page can tell you?
Every page on this site rests on a specific labelled dosing framework, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for your prescriber or dispensing pharmacist.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide maintenance dose.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
What is a maintenance dose?
The dose continued after escalation, chosen by a prescriber to balance effect and tolerability.
Do I need to reach 15 mg?
No. Many people maintain on a lower tolerated dose.
Can I lower my dose and keep results?
SURMOUNT-MAINTAIN tested exactly this. Reducing to 5 mg maintained -16.6% bodyweight reduction versus -21.9% on the maximum tolerated dose and -9.9% on placebo (SURMOUNT-MAINTAIN, Lancet 2026), so a reduced dose is a supported alternative to stopping.
Is a lower dose the same as microdosing?
No — maintenance lowers an already-effective dose under supervision; microdosing starts below the studied range without randomised evidence.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.